SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness
In order to support vaccine development, and to aid convalescent plasma therapy, it would be important to understand the kinetics, timing and persistence of SARS-CoV-2 neutralizing antibodies (NAbs), and their association with clinical disease severity. Therefore, we used a surrogate viral neutraliz...
| Auteurs principaux: | , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Langue: | English |
| Publié: |
Springer Nature
2021
|
| Sujets: |